Elanco Animal Health (NASDAQ:ELAN) Director John P. Bilbrey purchased 7,750 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average price of $32.39 per share, for a total transaction of $251,022.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Elanco Animal Health stock traded up $0.48 during midday trading on Thursday, reaching $33.08. 2,186,459 shares of the stock were exchanged, compared to its average volume of 7,803,570. Elanco Animal Health has a 52 week low of $28.00 and a 52 week high of $37.61.
Elanco Animal Health (NASDAQ:ELAN) last posted its earnings results on Thursday, May 9th. The company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.03. The firm had revenue of $731.10 million for the quarter, compared to the consensus estimate of $743.40 million. The business’s revenue was down .7% on a year-over-year basis. During the same period last year, the company posted $0.33 EPS.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Elanco Animal Health in the 3rd quarter worth approximately $32,247,000. JPMorgan Chase & Co. acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $38,358,000. LPL Financial LLC acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $313,000. Legal & General Group Plc acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $839,000. Finally, Morgan Stanley acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $314,448,000.
ELAN has been the topic of a number of recent research reports. BMO Capital Markets upped their price target on shares of Elanco Animal Health from $32.00 to $35.00 and gave the company a “market perform” rating in a research note on Friday, May 10th. Zacks Investment Research cut shares of Elanco Animal Health from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. UBS Group began coverage on shares of Elanco Animal Health in a research note on Wednesday, January 23rd. They set a “sell” rating and a $29.00 price target on the stock. Bank of America raised shares of Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $30.95 target price on the stock in a report on Monday, March 18th. Finally, Morgan Stanley began coverage on shares of Elanco Animal Health in a report on Wednesday, March 13th. They set an “equal weight” rating and a $34.00 target price on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. Elanco Animal Health presently has an average rating of “Hold” and an average target price of $33.47.
About Elanco Animal Health
There is no company description available for Elanco Animal Health Inc
See Also: Dividend Aristocrat Index
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.